

Contents

Preface to the first edition — VII

Preface to the second edition — XIII

About the author — XXIII

1 Acetylcholine — 1

- 1.1 Goals — 1
- 1.2 Nerve transmission through the synapse — 1
- 1.3 Cholinergic nervous system: muscarinic and nicotinic receptors — 2
- 1.4 Direct agonist drugs — 6
- 1.5 Molecular modifications of ACh — 6
 - 1.5.1 Modifications in the ammonium moiety — 6
 - 1.5.2 Modifications to the ethylene bridge — 8
 - 1.5.3 Modifications in the acyloxy group — 9
 - 1.5.3.1 Ester hydrolysis — 9
 - 1.5.3.2 Neighboring group participation — 9
 - 1.5.3.3 Electronic effects — 11
- 1.6 Synthesis of methacholine and bethanechol — 12
- 1.7 Muscarinic drugs derived from other models — 12
- 1.8 Clinical uses of cholinergic agonists — 13
 - 1.8.1 Muscarinic agonists — 13
 - 1.8.2 Nicotinic agonists — 13
- 1.9 Muscarinic antagonists: clinical effects — 13
 - 1.9.1 Clinical uses — 14
- 1.10 Muscarinic antagonists — 14
 - 1.10.1 Atropine — 14
 - 1.10.2 Hyoscine — 15
- 1.11 Structural analogs based on atropine — 16
- 1.12 Anticholinergic drugs obtained by synthesis: structure–activity relationships — 16
- 1.13 M2 antimuscarinic drugs — 17
- 1.14 Disconnection and syntheses of aminoalkyl esters — 18
 - 1.14.1 Simple alcohol disconnections — 20
 - 1.14.1.1 Cyclopentolate — 20
 - 1.14.2 Aminoesters — 21
 - 1.14.3 Aminopropanols — 21
- 1.15 Amidoammonium drugs — 22
- 1.16 Antagonist drugs on nicotinic receptors — 23
 - 1.16.1 Decamethonium and suxamethonium — 25

1.16.2	Atracurium — 26
1.17	Anticholinesterases and acetylcholinesterase — 27
1.17.1	Effect of anticholinesterases — 27
1.17.2	Acetylcholinesterase active center — 28
1.17.2.1	Binding interactions at the active site — 28
1.17.2.2	The mechanism of hydrolysis — 29
1.17.3	Anticholinesterase drugs — 29
1.17.3.1	Carbamates — 29
1.17.3.2	Organophosphorus compounds — 33
1.18	Fundamentals — 36

2 Noradrenaline (norepinephrine) — 37

2.1	Goals — 37
2.2	Introduction — 37
2.3	Adrenergic synapses — 37
2.4	Drugs that focus on noradrenaline biosynthesis: false transmitters — 38
2.5	Drugs that affect the release of stored noradrenaline — 39
2.6	Mechanism of action of MAO — 42
2.7	Adrenergic indirect drugs — 43
2.8	Catechol- <i>O</i> -methyltransferase inhibitors (COMT) — 46
2.9	Direct adrenergic drugs (postsynaptic agonists) — 46
2.9.1	Selectivity for α -adrenoreceptors versus β — 48
2.9.1.1	Substitution of the <i>N</i> -alkyl group — 48
2.10	Adrenergic β -blockers — 53
2.10.1	Regioselective opening of epoxides in basic media — 55
2.10.2	Regioselective opening of epoxides in acidic media — 56
2.11	α -Adrenergic blockers — 59
2.11.1	Competitive antagonists of NA and adrenaline — 59
2.11.2	Noncompetitive antagonists of NA, especially β -haloethylamines, capable of irreversibly alkylating the receptor — 60
2.11.3	Benzodioxanes and other synthetic heterocycles: imidazolines — 60
2.12	Fundamentals — 62

3 Dopamine — 63

3.1	Goals — 63
3.2	Introduction: antiparkinsonians related to the action or release of dopamine — 63
3.2.1	Conformationally restricted dopamine congeners — 64
3.3	Direct agonists — 65
3.4	MAO and COMT inhibitors — 66

- 3.5 Drugs capable of causing the release of dopamine from the peripheral neural sites at the presynaptic level — **67**
- 3.6 Other dopaminergic agonists — **69**
- 3.7 Dopaminergic antagonists — **70**
- 3.7.1 Tricyclic neuroleptics: phenothiazines and thioxanthenes — **70**
- 3.7.1.1 Synthesis of the tricyclic system — **71**
- 3.7.1.2 Pharmacophore of tricyclic neuroleptics — **75**
- 3.7.2 Butyrophenones and analogs — **77**
- 3.7.2.1 Mannich reaction — **77**
- 3.7.3 *Ortho*-Methoxybenzamides (orthopramides) — **81**
- 3.8 Fundamentals — **82**

- 4 Serotonin and reuptake inhibitors of biogenic amines — 83**
- 4.1 Goals — **83**
- 4.2 Introduction — **83**
- 4.3 Reuptake inhibitors: tricyclic antidepressants — **83**
- 4.4 MAO inhibitors (MAOIs) — **85**
- 4.5 Serotonin — **86**
- 4.6 Selective serotonin reuptake inhibitors (SSRIs) — **88**
- 4.7 Direct action on serotonergic receptors — **88**
- 4.7.1 5-HT_{1D} agonists: antimigraine drugs — **88**
- 4.7.1.1 Sumatriptan and other triptans — **89**
- 4.7.2 5-HT_{1A} agonists — **92**
- 4.7.3 5-HT₃ antagonists — **93**
- 4.8 Summary — **95**
- 4.9 Fundamentals — **96**

- 5 Amino acid neurotransmitters — 97**
- 5.1 Goals — **97**
- 5.2 Introduction — **97**
- 5.3 Inhibitors of γ -aminobutyric acid (GABA) — **97**
- 5.4 Presynaptic modulators — **98**
- 5.5 Enzyme inhibitors that have pyridoxal phosphate as cofactor — **99**
- 5.6 Postsynaptic modulators — **102**
- 5.6.1 Benzodiazepines — **103**
- 5.6.1.1 Mechanism of the rearrangement reaction to 1,4-benzodiazepines — **105**
- 5.6.1.2 Mechanism of metabolic hydrolysis of chlordiazepoxide (Librium[®], 1960) — **105**
- 5.6.1.3 Second-generation benzodiazepines [diazepam (Valium[®])] — **106**
- 5.6.1.4 Structure–activity relationships — **106**
- 5.6.2 Fixation of steroids to GABA_A — **109**

- 5.6.3 Other drugs related to benzodiazepines — **110**
- 5.6.4 Barbituric acids (or barbiturates) — **110**
- 5.7 Fundamentals — **114**

6 Peptides as neurotransmitters: narcotic analgesics — 115

- 6.1 Goals — **115**
- 6.2 Morphine — **115**
 - 6.2.1 Structure–activity relationships of morphine — **116**
 - 6.2.1.1 The phenolic group — **116**
 - 6.2.1.2 Alcohol at position 6 — **116**
 - 6.2.1.3 The 7–8 double bond — **117**
 - 6.2.1.4 The *N*-methyl group — **118**
 - 6.2.1.5 E ring and the ethereal bridge — **118**
 - 6.2.1.6 Stereochemistry — **118**
 - 6.2.2 Development of morphine analogs: strategies — **120**
 - 6.2.2.1 Extension of the drug: addition of “extra” binding groups — **120**
 - 6.2.2.2 Simplification or dissection of the drug — **123**
 - 6.2.2.3 Increased rigidity — **129**
 - 6.2.3 Multiple analgesic receptors — **131**
 - 6.2.3.1 Mu receptor (μ) — **131**
 - 6.2.3.2 Kappa receptor (κ) — **132**
 - 6.2.3.3 Delta receptor (δ) — **132**
 - 6.2.4 Pain scale — **133**
 - 6.2.5 Agonists and antagonists — **133**
 - 6.2.6 Enkephalins and endorphins — **135**
 - 6.2.7 Enkephalin analogs — **136**
- 6.3 Preliminary colorimetric methods to detect drugs of abuse by police forces — **136**
 - 6.3.1 Identification of morphine — **137**
 - 6.3.2 Identification of morphine, codeine, and heroin — **137**
 - 6.3.3 Identification of methadone — **138**
 - 6.3.4 Identification of amphetamine/methamphetamine — **138**
 - 6.3.5 Identification of cocaine — **138**
- 6.4 Fundamentals — **140**

7 Histamine and antihistamines — 141

- 7.1 Goals — **141**
- 7.2 Histamine — **141**
 - 7.2.1 H1-antihistamines: synthesis and SARs — **143**
 - 7.2.2 Second-generation H1-antihistamine drugs — **148**
- 7.3 Cimetidine: example of a rational approach in the design of a drug — **151**

7.3.1	Beginnings: ulcer therapy in 1964 —	151
7.3.2	Two histamine receptors —	152
7.3.3	Looking for a leader: histamine —	153
7.4	Searching for a leader: N^{α} -guanylhistamine —	154
7.5	The theory of chelation —	158
7.6	From a partial agonist to an antagonist: development of burimamide —	158
7.7	Development of methiamide —	159
7.8	Cimetidine development —	162
7.8.1	Cimetidine metabolism —	165
7.8.2	Bredereck reaction —	165
7.8.2.1	Cimetidine synthesis —	165
7.8.3	Conformational isomers of cimetidine —	166
7.8.4	Desolvation —	168
7.8.5	Development of the 2-nitroethene-1,1-diamine group —	170
7.9	Variation of the imidazole ring and the cyanoguanidine moiety of cimetidine: ranitidine —	172
7.10	Summary of cimetidine design —	173
7.11	Comparison between H1 and H2 antagonists —	173
7.12	Fundamentals —	174
8	Enzymatic inhibitors I —	175
8.1	Goals —	175
8.2	Introduction —	175
8.3	Carbonic anhydrase (CA) inhibitors —	175
8.4	Renin-angiotensin pathway —	178
8.4.1	Angiotensin II antagonists: X-ray crystallographic studies —	179
8.5	Fundamentals —	184
9	Enzymatic inhibitors II —	185
9.1	Goals —	185
9.2	Introduction —	185
9.3	Classification of nonsteroidal anti-inflammatory drugs (NSAIDs) —	189
9.3.1	Arylacetic acids or “fenacs” —	189
9.3.1.1	Blanc chloromethylation or Blanc reaction —	189
9.3.1.2	Reduction of Wolff-Kishner —	193
9.3.2	Arylpropionic acids or “profens” —	194
9.3.3	Naproxen —	194
9.3.4	<i>N</i> -Arylanthranilic (fenamic) acids —	195
9.3.5	Enols (oxicams) —	196
9.3.6	COX-2 selective inhibitors: coxibs —	197
9.4	Fundamentals —	199

10	Design of drugs acting on transport through biological membranes — 200
10.1	Goals — 200
10.2	Design of drugs that act on transport through cell membranes — 200
10.3	Voltage-gated sodium channels — 200
10.3.1	Local anesthetics — 203
10.3.1.1	Structure–activity relationships in local anesthetics — 204
10.3.1.2	Physicochemical properties and mode of action — 206
10.4	Voltage-dependent calcium channels — 206
10.4.1	Calcium channel blockers: structural families — 207
10.4.1.1	1,4-Dihydropyridines — 207
10.4.1.2	Agents that act as activators of K^+ — 208
10.4.2	H^+/K^+ -ATPase inhibitors: antiulcer drugs — 210
10.5	Fundamentals — 211
11	Enzymatic inhibition: inhibitors of the biosynthesis of the cellular wall — 212
11.1	Goals — 212
11.2	Antibiotics — 212
11.3	Penicillins — 212
11.3.1	Structure of penicillins — 213
11.3.2	Various penicillins — 213
11.3.3	Properties of penicillin G — 214
11.3.4	Structure–activity relationships of penicillins — 215
11.3.5	Sensitivity of penicillin G to acids — 215
11.3.5.1	Ring strain — 215
11.3.5.2	The highly reactive carbonyl group of the β -lactam system — 215
11.3.5.3	Influence of the acyclic lateral chain (neighboring-group participation) — 216
11.3.5.4	Facing the problem of acid sensitivity — 216
11.3.6	Penicillins sensitive to β -lactamases — 216
11.3.7	Facing the problem of β -lactamase sensitivity — 218
11.3.8	Resistance to penicillins — 220
11.3.8.1	Permeability barrier — 221
11.3.8.2	High levels of the enzyme transpeptidase — 222
11.3.8.3	Presence of β -lactamases — 222
11.3.9	Addressing the narrow-spectrum problem — 222
11.4	Cephalosporins — 225
11.4.1	SARs of cephalosporin C — 228
11.4.2	Cephalosporin C analogs by variation of the 7-acylamine side chain — 228

- 11.4.3 Cephalosporin C analogs by variation of the 3-acetoxymethyl side chain — **230**
- 11.4.4 Synthesis of 3-methylated cephalosporins — **231**
- 11.4.5 Disclaimer — **231**
- 11.4.6 Summary of the properties of cephalosporins — **231**
- 11.5 Clavulanic acid (Beechams, 1976) — **232**
- 11.6 Mechanism of action of penicillins and cephalosporins — **233**
- 11.7 Fundamentals — **238**

12 Enzymatic inhibition: other antibacterial agents — 239

- 12.1 Goals — **239**
- 12.2 Introduction — **239**
- 12.3 SARs — **239**
- 12.4 Sulfanilamide analogs — **240**
- 12.5 Applications of sulfonamides — **241**
- 12.6 Mechanism of action — **242**
- 12.7 Synthesis of sulfonamides — **244**
- 12.8 Examples of other antimetabolites — **245**
- 12.8.1 Trimethoprim — **246**
- 12.9 Antibacterial agents affecting protein synthesis — **246**
- 12.9.1 Rifamycins — **246**
- 12.9.2 Aminoglycosides — **247**
- 12.9.3 Tetracyclines — **247**
- 12.9.4 Chloramphenicol — **248**
- 12.9.4.1 Aldol reaction — **248**
- 12.9.4.2 Nitro-alcohol reaction or the Henry reaction — **249**
- 12.9.5 Erythromycin — **250**
- 12.9.6 Aminoacridines — **250**
- 12.9.7 1,8-Naphthyridine and fluoroquinolones — **253**
- 12.9.7.1 Orthoester — **254**
- 12.9.7.2 Synthesis of diethyl ethoxymethylenemalonate, intermediate for the preparation of norfloxacin and nalidixic acid — **255**
- 12.10 Why 4-quinolone-3-carboxylic acids do not decarboxylate despite being β -ketoacids? — **257**
- 12.11 Fundamentals — **258**

13 Enzymatic inhibition: inhibitors of biosynthesis of nitrogenous bases — 259

- 13.1 Goals — **259**
- 13.2 Introduction — **259**
- 13.3 Nucleic acids — **259**
- 13.4 The birth of cancer chemotherapy: accident and research — **259**

13.5	Thymidylate synthase inhibitors —	261
13.5.1	Tetrahydrofolic acid —	262
13.5.2	5-Fluorouracil (5-FU) —	263
13.6	DHFR inhibitors —	267
13.7	Tyrosine kinase inhibitors —	267
13.7.1	Structure of tyrosine kinase receptors —	269
13.7.2	Mechanisms of activation of the EGF receptor tyrosine kinase —	269
13.7.3	Example of a kinase inhibitor for clinical use (gefitinib) —	270
13.8	Antivirals —	271
13.8.1	Antiviral inhibitors of DNA polymerases and other enzymes —	272
13.9	Fundamentals —	275

Index —	277
----------------	------------